Opinion statement
The rates of depression, anxiety, and sleep disturbance (suicide risk factors) are greater in patients with allergic rhinitis than in the general population. The rate of allergy is also greater in patients with depression. Preliminary data suggest that patients with a history of allergy may have an increased rate of suicide. Clinicians should actively inquire to diagnose allergy in patients with depression and depression in patients with allergy.
Spring peaks of suicide are highly replicated, but their origin is poorly understood. Preliminary epidemiologic data suggest that seasonal spring peaks in aeroallergens are associated with seasonal spring peaks in suicide. Our research in Brown Norway rats demonstrates that sensitization and exposure to aeroallergens induces anxiety-like and aggressive behaviors as well as allergy-related helper T-cell type 2 (Th2) cytokine gene expression in the prefrontal cortex. Thus, it is possible that sensitization and exposure to aeroallergens, which peak in spring, may be conducive to seasonal exacerbation of suicide risk factors such as anxiety, depression, hostility/aggression, and sleep disturbance. Connecting allergy with suicide and suicide risk factors adds to previous neurologic literature connecting allergy with migraines and seizure disorders.
Our recent report of Th2 (allergy-mediating) cytokine expression in the orbitofrontal cortex of suicide victims should lead to future studies to test the hypothesis that mediators of allergic inflammation in the nasal cavities may result in Th2 cytokine expression in the brain, influencing affect and behavioral modulation.
Certain medications used to treat allergy can exacerbate suicide risk factors, potentially worsening suicide risk and even triggering suicide. Systemic (but not topical) corticosteroids have been associated with manic and depressive episodes and mixed mood states. Recently, the US Food and Drug Administration started investigating the possibility that montelukast may trigger suicide. Although this association requires further exploration and confirmation, clinicians should err on the side of caution, inquiring about past suicide attempts; hopelessness; reasons for living; and suicidal ideation, intent, or plan; and referring the patient to a mental health professional for evaluation if appropriate.
Similar content being viewed by others
References and Recommended Reading
Mann JJ: Neurobiology of suicidal behaviour. Nat Rev Neurosci 2003, 4: 819–828.
Goodwin FK, Jamison KR: Manic Depressive Illness: Bipolar Disorders and Recurrent Depression, edn 2. New York: Oxford University Press; 2007.
American Academy of Allergy Asthma & Immunology: National Allergy Bureau. Available at http://www.aaaai.org/nab/index.cfm. Accessed June 19, 2008.
Kosisky SE, Carpenter GB: Predominant tree aeroallergens of the Washington, DC area: a six year survey (1989–1994) Ann Allergy Asthma Immunol 1997, 78: 381–392.
Postolache TT, Stiller JW, Herrell R, et al.: Tree pollen peaks are associated with increased nonviolent suicide in women. Mol Psychiatry 2005, 10: 232–235.
Timonen M, Jokelainen J, Hakko H, et al.: Atopy and depression: results from the Northern Finland 1966 Birth Cohort Study. Mol Psychiatry 2003, 8: 738–744.
Marshall PS, O’Hara C, Steinberg P: Effects of seasonal allergic rhinitis on fatigue levels and mood. Psychosom Med 2002, 64: 684–691.
Guzman A, Tonelli LH, Roberts D, et al.: Mood-worsening with high-pollen-counts and seasonality: a preliminary report. J Affect Disord 2007, 101: 269–274.
Postolache TT, Lapidus M, Sander ER, et al.: Changes in allergy symptoms and depression scores are positively correlated in patients with recurrent mood disorders exposed to seasonal peaks in aeroallergens. ScientificWorldJournal 2007, 7: 1968–1977.
Postolache TT, Langenberg PB, Zimmerman SA, et al.: Changes in severity of allergy and anxiety symptoms are positively correlated in patients with recurrent mood disorders who are exposed to seasonal peaks of aeroallergens. Int J Child Health Hum Dev (in press).
Bell IR, Jasnoski ML, Kagan J, et al.: Depression and allergies: survey of a nonclinical population. Psychother Psychosom 1991, 55: 24–31.
Hashiro M, Okumura M: The relationship between the psychological and immunological state in patients with atopic dermatitis. J Dermatol Sci 1998, 16: 231–235.
Timonen M, Jokelainen J, Silvennoinen-Kassinen S, et al.: Association between skin test diagnosed atopy and professionally diagnosed depression: a Northern Finland 1966 Birth Cohort study. Biol Psychiatry 2002, 52: 349–355.
Timonen M, Jokelainen J, Herva A, et al.: Presence of atopy in first-degree relatives as a predictor of a female proband’s depression: results from the Northern Finland 1966 Birth Cohort. J Allergy Clin Immunol 2003, 111: 1249–1254.
Wamboldt MZ, Hewitt JK, Schmitz S, et al.: Familial association between allergic disorders and depression in adult Finnish twins. Am J Med Genet 2000, 96: 146–153.
Wilken JA, Berkowitz R, Kane R: Decrements in vigilance and cognitive functioning associated with ragweed-induced allergic rhinitis. Ann Allergy Asthma Immunol 2002, 89: 372–380.
Hurwitz EL, Morgenstern H: Cross-sectional associations of asthma, hay fever, and other allergies with major depression and low-back pain among adults aged 20–39 years in the United States. Am J Epidemiol 1999, 150: 1107–1116.
Addolorato G, Ancona C, Capristo E, et al.: State and trait anxiety in women affected by allergic and vasomotor rhinitis. J Psychosom Res 1999, 46: 283–289.
Prolo P, Licinio J: Cytokines in affective disorders and schizophrenia: new clinical and genetic findings. Mol Psychiatry 1999, 4: 396.
Capuron L, Ravaud A, Gualde N, et al.: Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy. Psychoneuroendocrinology 2001, 26: 797–808.
Dantzer R, Wollman EE, Yirmiya R: Cytokines and depression: an update. Brain Behav Immun 2002, 16: 501–502.
Capuron L, Dantzer R: Cytokines and depression: the need for a new paradigm. Brain Behav Immun 2003, 17(Suppl 1): S119–S124.
Anisman H, Merali Z, Poulter MO, et al.: Cytokines as a precipitant of depressive illness: animal and human studies. Curr Pharm Des 2005, 11: 963–972.
Schiepers OJ, Wichers MC, Maes M: Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29: 201–217.
Raison CL, Capuron L, Miller AH: Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006, 27: 24–31.
Dantzer R, Kelley KW: Twenty years of research on cytokine-induced sickness behavior. Brain Behav Immun 2007, 21: 153–160.
Dieperink E, Willenbring M, Ho SB: Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry 2000, 157: 867–876.
Crone CC, Gabriel GM, Wise TN: Managing the neuropsychiatric side effects of interferon-based therapy for hepatitis C. Cleve Clin J Med 2004, 71(Suppl 3): S27–S32.
Raison CL, Demetrashvili M, Capuron L, et al.: Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 2005, 19: 105–123.
Denicoff KD, Rubinow DR, Papa MZ, et al.: The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med 1987, 107: 293–300.
Capuron L, Ravaud A, Dantzer R: Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy. J Clin Oncol 2000, 18: 2143–2151.
Capuron L, Dantzer R, Miller AH: Neuro-immune interactions in psychopathology with the example of interferon alpha-induced depression. J Soc Biol 2003, 197: 151–156.
Frommberger UH, Bauer J, Haselbauer P, et al.: Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur Arch Psychiatry Clin Neurosci 1997, 247: 228–233.
Levine J, Barak Y, Chengappa KN, et al.: Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology 1999, 40: 171–176.
Yirmiya R, Weidenfeld J, Pollack Y, et al.: Cytokines, “depression due to a general medical condition,” and antidepressant drugs. Adv Exp Med Biol 1999, 461: 283–316.
Dunn AJ, Swiergiel AH, de Beaurepaire R: Cytokines as mediators of depression: What can we learn from animal studies? Neurosci Biobehav Rev 2005, 29: 891–909.
Dunn AJ, Swiergiel AH: Effects of interleukin-1 and endotoxin in the forced swim and tail suspension tests in mice. Pharmacol Biochem Behav 2005, 81: 688–693.
Swiergiel AH, Dunn AJ: Effects of interleukin-1beta and lipopolysaccharide on behavior of mice in the elevated plusmaze and open field tests. Pharmacol Biochem Behav 2007, 86: 651–659.
Reichenberg A, Yirmiya R, Schuld A, et al.: Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001, 58: 445–452.
De La Garza R: Endotoxin-or pro-inflammatory cytokine-induced sickness behavior as an animal model of depression: focus on anhedonia. Neurosci Biobehav Rev 2005, 29: 761–770.
Engeland CG, Kavaliers M, Ossenkopp KP: Sex differences in the effects of muramyl dipeptide and lipopolysaccharide on locomotor activity and the development of behavioral tolerance in rats. Pharmacol Biochem Behav 2003, 74: 433–447.
Tonelli LH, Stiller J, Rujescu D, et al.: Elevated cytokine expression in the orbitofrontal cortex of victims of suicide. Acta Psychiatr Scand 2008, 117: 198–206.
Tonelli LH, Holmes A, Postolache TT: Intranasal immune challenge induces sex-dependent depressive-like behavior and cytokine expression in the brain. Neuropsychopharmacology 2008, 33: 1038–1048.
Tonelli LH, Virk G, Joppy B, et al.: Experimentally induced allergy to tree pollen induces depressive-like behavior and mast cell activation in the brain of female rats. Society of Biological Psychiatry Annual Meeting, Toronto, Canada; 2006.
Tonelli LH, Hoshino A, Katz M, et al.: Acute stress promotes aggressive-like behavior in rats made allergic to tree pollen. Int J Child Health Hum Dev (in press).
Goehler LE, Gaykema RP, Hansen MK, et al.: Vagal immune-to-brain communication: a visceral chemosensory pathway. Auton Neurosci 2000, 85: 49–59.
Quan N, Herkenham M: Connecting cytokines and brain: a review of current issues. Histol Histopathol 2002, 17: 273–288.
Pitossi F, del Ray A, Kabiersch A, et al.: Induction of cytokine transcripts in the central nervous system and pituitary following peripheral administration of endotoxin to mice. J Neurosci Res 1997, 48: 287–298.
Molina-Holgado F, Toulmond S, Rothwell NJ: Involvement of interleukin-1 in glial responses to lipopolysaccharide: endogenous versus exogenous interleukin-1 actions. J Neuroimmunol 2000, 111: 1–9.
Turrin NP, Plata-Salamán CR: Cytokine-cytokine interactions and the brain. Brain Res Bull 2000, 51: 3–9.
Vitkovic L, Konsman JP, Bockaert J, et al.: Cytokine signals propagate through the brain. Mol Psychiatry 2000, 5: 604–615.
Rivest S: Molecular insights on the cerebral innate immune system. Brain Behav Immun 2003, 17: 13–19.
Turnbull AV, Rivier C: Regulation of the HPA axis by cytokines. Brain Behav Immun 1995, 9: 253–275.
Tonelli LH, Postolache TT, Sternberg EM: Inflammatory genes and neural activity: involvement of immune genes in synaptic function and behavior. Front Biosci 2005, 10: 675–680.
Quan N, Zhang Z, Demetrikopoulos MK: Evidence for involvement of B lymphocytes in the surveillance of lung metastasis in the rat. Cancer Res 1999, 59: 1080–1089.
Tonelli LH, Maeda S, Rapp KL, et al.: Differential induction of interleukin-I beta mRNA in the brain parenchyma of Lewis and Fischer rats after peripheral injection of lipopolysaccharides. J Neuroimmunol 2003, 140: 126–136.
Tonelli LH, Postolache TT: Tumor necrosis factor alpha, interleukin-1 beta, interleukin-6 and major histocompatibility complex molecules in the normal brain and after peripheral immune challenge. Neurol Res 2005, 27: 679–684.
Singareddy RK, Balon R: Sleep and suicide in psychiatric patients. Ann Clin Psychiatry 2001, 13: 93–101.
Fawcett J, Scheftner WA, Fogg L, et al.: Time-related predictors of suicide in major affective disorder. Am J Psychiatry 1990, 147: 1189–1194.
Krueger JM, Walter J, Dinarello CA, et al.: Sleep-promoting effects of endogenous pyrogen (interleukin-1). Am J Physiol 1984, 246: R994–R999.
Opp MR, Krueger JM: Interleukin 1-receptor antagonist blocks interleukin 1-induced sleep and fever. Am J Physiol 1991, 260: R453–R457.
Kapas L, Krueger JM: Tumor necrosis factor-beta induces sleep, fever, and anorexia. Am J Physiol 1992, 263: R703–R707.
Gemma C, Imeri L, de Simoni MG, et al.: Interleukin-1 induces changes in sleep, brain temperature, and serotonergic metabolism. Am J Physiol 1997, 272: R601–R606.
Hogan D, Morrow JD, Smith EM, et al.: Interleukin-6 alters sleep of rats. J Neuroimmunol 2003, 137: 59–66.
Kushikata T, Fang J, Wang Y, Krueger JM: Interleukin-4 inhibits spontaneous sleep in rabbits. Am J Physiol 1998, 275: R1185–R1191.
Kushikata T, Fang J, Krueger JM: Interleukin-10 inhibits spontaneous sleep. J Interferon Cytokine Res 1999, 19: 1025–1030.
Vgontzas AN, Chrousos GP: Sleep, the hypothalamicpituitary-adrenal axis, and cytokines: multiple interactions and disturbances in sleep disorders. Endocrinol Metab Clin North Am 2002, 31: 15–36.
Hughes K, Glass C, Ripchinski M, et al.: Efficacy of the topical nasal steroid budesonide on improving sleep and daytime somnolence in patients with perennial allergic rhinitis. Allergy 2003, 58: 380–385.
Hamano N, Terada N, Maesako K, et al.: Effect of sex hormones on eosinophilic inflammation in nasal mucosa. Allergy Asthma Proc 1998, 19: 263–269.
Vliagoftis H, Dimitriadou V, Boucher W, et al.: Estradiol augments while tamoxifen inhibits rat mast cell secretion. Int Arch Allergy Immunol 1992, 98: 398–409.
Osman M: Therapeutic implications of sex differences in asthma and atopy. Arch Dis Child 2003, 88: 587–590.
Illum L: Is nose-to-brain transport of drugs in man a reality? J Pharm Pharmacol 2004, 56: 3–17.
Thorne RG, Pronk GJ, Padmanabhan V: Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 2004, 127: 481–496.
Mori I, Goshima F, Ito H, et al.: The vomeronasal chemosensory system as a route of neuroinvasion by herpes simplex virus. Virology 2005, 334: 51–58.
Loftus LT, Li HF, Gray AJ, et al.: In vivo protein transduction to the CNS. Neuroscience 2006, 139: 1061–1067.
Kalueff AV, Lehtimaki KA, Ylinen A, et al.: Intranasal administration of human IL-6 increases the severity of chemically induced seizures in rats. Neurosci Lett 2004, 365: 106–110.
Pelidou SH, Zou LP, Deretzi G, et al.: Enhancement of acute phase and inhibition of chronic phase of experimental autoimmune neuritis in Lewis rats by intranasal administration of recombinant mouse interleukin 17: potential immunoregulatory role. Exp Neurol 2000, 163: 165–172.
Annesi-Maesano I: Epidemiological evidence of the occurrence of rhinitis and sinusitis in asthmatics. Allergy 1999, 54(Suppl 57): 7–13.
Dykewicz MS, Fineman S, Skoner DP, et al.: Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol 1998, 81: 478–518.
The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee: Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. Lancet 1998, 351: 1225–1232.
Bousquet J, Van Cauwenberge P, Khaltaev N: Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001, 108(5 Suppl): S147–S334.
Dykewicz MS: Rhinitis and sinusitis. J Allergy Clin Immunol 2003, 111(2 Suppl): S520–S529.
Demoly P, Allaert FA, Lecasble M, Bousquet J: Validation of the classification of ARIA (allergic rhinitis and its impact on asthma). Allergy 2003, 58: 672–675.
Ku M, Silverman B, Prifti N, et al.: Prevalence of migraine headaches in patients with allergic rhinitis. Ann Allergy Asthma Immunol 2006, 97: 226–230.
Low NC, Merikangas KR: The comorbidity of migraine. CNS Spectr 2003, 8: 433–434, 437–444.
Frediani T, Lucarelli S, Pelliccia A, et al.: Allergy and childhood epilepsy: a close relationship? Acta Neurol Scand 2001, 104: 349–352.
Theoharides TC, Donelan J, Kandere-Grzybowska, et al.: The role of mast cells in migraine pathophysiology. Brain Res Rev 2005, 49: 65–76.
Boyce JA; Mast cells: beyond IgE. J Allergy Clin Immunol 2003, 111: 24–32.
Berger WE: Treatment update: allergic rhinitis. Allergy Asthma Proc 2001, 22: 191–198.
Borish L: Allergic rhinitis: systemic inflammation and implications for management. J Allergy Clin Immunol 2003, 112: 1021–1031.
Hamilton RG, Adkinson NF Jr.: Clinical laboratory assessment of IgE-dependent hypersensitivity. J Allergy Clin Immunol 2003, 111(2 Suppl): S687–S701.
Tomooka LT, Murphy C, Davidson TM: Clinical study and literature review of nasal irrigation. Laryngoscope 2000, 110: 1189–1193.
Weiner JM, Abramson MJ, Puy RM: Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ 1998, 317: 1624–1629.
Yàñez A, Rodrigo GJ: Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. Ann Allergy Asthma Immunol 2002, 89: 479–484.
Rodrigo GJ, Yàñez A: The role of antileukotriene therapy in seasonal allergic rhinitis: a systematic review of randomized trials. Ann Allergy Asthma Immunol 2006, 96: 779–786.
Chait LD: Factors influencing the reinforcing and subjective effects of ephedrine in humans. Psychopharmacology (Berl) 1994, 113: 381–387.
Meltzer EO, Weiler JM, Widlitz MD: Comparative outdoor study of the efficacy, onset and duration of action, and safety of cetirizine, loratadine, and placebo for seasonal allergic rhinitis. J Allergy Clin Immunol 1996, 97: 617–626.
US Food and Drug Administration: Early communication about an ongoing safety review of montelukast (Singulair). March 27, 2008. Available at http://www.fda.gov/cder/drug/early_comm/montelukast.htm
Brozek JL, Baena-Cagnani CE, Bonini S, et al.: Methodology for development of the Allergic Rhinitis and its Impact on Asthma guideline 2008 update. Allergy 2008, 63: 38–46.
Calderon MA, Alves B, Jacobson M, et al.: Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007, CD001936.
Radulovic S, Calderon MA, Wilson DR, et al.: Safety profile of sublingual immunotherapy (SLIT) for allergic rhinitis (AR). J Allergy Clin Immun 2008, 121: S142.
Didier A, Malling H, Worm M, et al.: Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007, 120: 1338–1345.
Kaliner MA: Omalizumab and the treatment of allergic rhinitis. Curr Allergy Asthma Rep 2004, 4: 237–244.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Postolache, T.T., Komarow, H. & Tonelli, L.H. Allergy: A risk factor for suicide?. Curr Treat Options Neurol 10, 363–376 (2008). https://doi.org/10.1007/s11940-008-0039-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11940-008-0039-4